TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

GlobeNewswire Inc. Logo GlobeNewswire Inc. By 4D Path
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

4D Path developed a computational platform that can predict chemotherapy response in early-stage triple-negative breast cancer using routine biopsy images, demonstrating potential for personalized cancer treatment prediction.

Insights
MYGN   neutral

Mentioned as a previous biomarker evaluator in the trial, with no specific positive or negative context